Flossbach Von Storch SE Boosts Stake in Stryker Corporation $SYK

Key Points

• Flossbach Von Storch SE increased its stake in Stryker by 3.2% in Q4, buying 8,823 shares to hold 284,245 shares worth about $99.9 million (≈0.07% of the company).
• Director Ronda E. Stryker sold 250,000 shares on Feb. 4 at an average price of $362.92 for ~$90.73 million, a 9.23% reduction in her holding; company insiders now own 4.6% of Stryker.
• Stryker beat Q4 estimates with $4.47 EPS vs. $4.40 and $7.17B revenue (+11.4% YoY), declared a $0.88 quarterly dividend (annual $3.52, 1.1% yield), and holds a consensus analyst rating of “Moderate Buy” with an average target of $421.11.

Flossbach Von Storch SE raised its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 3.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 284,245 shares of the medical technology company's stock after buying an additional 8,823 shares during the period. Flossbach Von Storch SE owned about 0.07% of Stryker worth $99,904,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Stryker by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company's stock valued at $11,917,396,000 after acquiring an additional 133,892 shares during the period. Alliancebernstein L.P. grew its position in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company's stock valued at $2,342,987,000 after acquiring an additional 741,542 shares during the last quarter. Legal & General Group Plc increased its stake in Stryker by 4.4% in the third quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company's stock worth $851,457,000 after purchasing an additional 96,662 shares during the period. Corient Private Wealth LLC lifted its position in shares of Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company's stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Stryker by 4.5% during the third quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company's stock valued at $689,404,000 after purchasing an additional 80,536 shares during the period. Institutional investors own 77.09% of the company's stock.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is owned by company insiders.

Stryker Stock Up 0.5%

NYSE:SYK opened at $329.09 on Tuesday. Stryker Corporation has a 1-year low of $319.32 and a 1-year high of $404.87. The company has a 50-day moving average of $349.03 and a 200 day moving average of $357.85. The firm has a market cap of $126.04 billion, a PE ratio of 39.18, a price-to-earnings-growth ratio of 1.92 and a beta of 0.92. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts' consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter last year, the firm posted $4.01 EPS. The company's revenue for the quarter was up 11.4% on a year-over-year basis. As a group, research analysts anticipate that Stryker Corporation will post 14.91 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker's dividend payout ratio (DPR) is currently 41.90%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on SYK shares. Robert W. Baird set a $437.00 price target on shares of Stryker in a report on Friday, January 30th. Raymond James Financial raised shares of Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 price objective for the company in a research report on Tuesday, January 6th. Piper Sandler restated an "overweight" rating on shares of Stryker in a research note on Tuesday, January 27th. Leerink Partners began coverage on shares of Stryker in a research report on Monday, April 13th. They set an "outperform" rating and a $410.00 target price on the stock. Finally, The Goldman Sachs Group lowered their price target on Stryker from $403.00 to $357.00 and set a "neutral" rating for the company in a report on Thursday, April 9th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $421.11.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.